

Table 12: **Vif**

HXB2 Location	Author Location	Sequence	Immunogen	Species(HLA)	References
Vif( )	Vif( )		DNA gag/pol, vif, and env vaccine	murine( )	[Kim (1997b)]
			<ul style="list-style-type: none"> <li>• A gag/pol, vif or env DNA vaccine, when delivered in conjunction with the plasmid encoding the co-stimulatory molecules B7 and IL-12, gave a dramatic increase in both the cytotoxic and proliferative responses in mice</li> <li>• When IL-12 was present, CTL response could be detected even without <i>in vitro</i> stimulation</li> </ul>		

Table 13: **Tat**

HXB2 Location	Author Location	Sequence	Immunogen	Species(HLA)	References
Tat(49–57)	Tat(49–57)	NOT AN EPITOPE	protein-peptide conjugate	murine( )	[Kim (1997a)]
			<ul style="list-style-type: none"> <li>• The Tat peptide RKKRRQRRR when conjugated to a protein can cause that protein to be taken up by APCs and presented to CTL</li> <li>• The system was demonstrated by vaccinating mice with an OVA-Tat peptide conjugate and immunizing H-2 K<sup>b</sup> mice</li> <li>• The CTL response to the H-2 K<sup>b</sup> specific OVA peptide SIINFEKL was stimulated</li> </ul>		
Tat( )	Tat( )		HIV-1 infection	human( )	[Froebel (1997)]
			<ul style="list-style-type: none"> <li>• Two HIV-1 infected children with contrasting disease courses were followed longitudinally – one died of AIDS, the other is a long term non-progressor</li> <li>• Reactivity against Gag, Pol, Env and Tat proteins was tested by PBMC bulk cultured cells reacting with protein expressed in vaccinia constructs in autologous EBV transformed B cells</li> <li>• The child who progressed consistently had CTL against Pol and Tat</li> <li>• The long term non-progressing child had no detectable CTL, but was heterozygous for a mutation in the CCR5 receptor and for HLA-B49, which has been shown to be associated with slower progression</li> </ul>		